AIDASH
17.1.2023 09:31:43 CET | Business Wire | Press release
The majority of businesses will struggle to meet net-zero goals without the use of carbon credits, but a lack of trust in the tool is stalling uptake and pushing corporate net-zero plans off track. This is one of the striking findings from a global survey of over 500 senior sustainability officers, commissioned by AiDash, a leading provider of vegetation management and other satellite- and AI-powered operations, maintenance, and sustainability solutions.
The ‘Carbon Offsetting in 2023’ study shows sustainability and carbon management are now mainstream concerns, with 97% of businesses including them in investment decisions, 79% of CSO’s already accountable to their boards or the public, 98% doing more than legally required to reduce emissions and 56% of businesses committed to net-zero targets on or before 2030.
However, over half of businesses (56%) do not have operational control over the majority of their greenhouse gas (GHG) emissions and nearly half (43%) use carbon offsets for hard-to-reduce GHG emissions alongside direct measures. As a result, many businesses cannot meet net-zero targets without the use of carbon credits.
Despite this critical need, the survey revealed a major lack of trust in carbon offsetting, with 41% of CSOs stating they do not use carbon credits as they do not adequately trust them. This comes at a time when many carbon offsetting projects are being shown to be inconsistently measured, inadequately monitored, and frequently failing to prove they are based on additional carbon captured.
Another revelation is the inconsistency in validation methods for carbon credits. 4% do not validate credits at all, 35% only buy from government or voluntary certified schemes, 43% are exploring working with credit rating agencies, 35% undertake their own validation or third-party due diligence and 41% use a combination of these methods. This lack of uniformity raises doubts surrounding the accuracy and comparability of corporate sustainability measurements.
With 89% of CSOs confirming they use KPI metrics to track the progress of their sustainability plans, it is essential that those metrics are watertight. However, the three biggest challenges to meeting net-zero goals are all data related:
- Collating reference data such as regional electricity and airline emissions factors (26%)
- Lack of common reporting frameworks (19%)
- Difficulty collating internal information (18%)
“Rather than waiting for governments to agree to regional or global frameworks, businesses are forging forward independently, making ambitious environmental commitments,” says Abhishek Vinod Singh, CEO, AiDash. “The intent and action is there but what these businesses desperately need is an organizational tool they can trust to accurately measure, monitor, track and validate the progress of their sustainability plans on their journey to net-zero.”
Carbon offsetting was not the only hot topic of the survey. It also revealed that CSOs are turning their eyes towards biodiversity. While only 24% currently include biodiversity impact in their sustainability strategies, 66% already have a role dedicated to biodiversity, with a substantial proportion intending to introduce one in the next two years. However, as it stands, legacy approaches to measuring biodiversity could hamper progress.
“Advances in satellite and AI technology can solve the vast majority of issues businesses are having collecting, analyzing and verifying their sustainability data,” continues Singh. “Our carbon solution not only provides measurements that meet carbon credit standards, but also continuous evidence to prove that credits are based on additional carbon captured and that carbon remains permanently in the ground, which is crucial for credible ESG reporting. By supporting how businesses apply carbon offsetting to their own land, we can save them up to 90% when compared with buying the equivalent from an escalating carbon credit market.
“For biodiversity, our solution can measure a host of complex environmental assets, allowing businesses to enhance natural capital metrics such as pollination, recreational benefits, and the value of food production. By analyzing 1,000s of sites in a matter of weeks, and utilizing one ecologist to verify the data captured, the AiDash solution can reduce biodiversity management operational expenditure by up to 75%, helping businesses adhere to impending legislation in the US, Europe, and UK.”
To download the complete survey results, visit https://www.aidash.com/resource/carbon-offsets-report-2023/
About AiDash
AiDash is an AI-first vertical SaaS company on a mission to transform operations, maintenance, and sustainability in industries with geographically distributed assets by using satellites and AI at scale. With access to a continual, near real-time stream of critical data, utilities, energy, mining, and other core industries can make more informed decisions and build optimized long-term plans, all while reducing costs, improving reliability, and achieving sustainability goals. To learn more about how AiDash is helping core industries become more resilient, efficient, and sustainable, visit www.aidash.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
